Edson X Albuquerque Selected Research

Galantamine (Galanthamine)

10/2020	Oral Pretreatment with Galantamine Effectively Mitigates the Acute Toxicity of a Supralethal Dose of Soman in Cynomolgus Monkeys Posttreated with Conventional Antidotes.
12/2011	Galantamine counteracts development of learning impairment in guinea pigs exposed to the organophosphorus poison soman: clinical significance.
12/2010	Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain.
1/2010	Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning.
1/2010	Magnetic resonance imaging reveals that galantamine prevents structural brain damage induced by an acute exposure of guinea pigs to soman.
12/2009	Effectiveness of donepezil, rivastigmine, and (+/-)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine.
7/2007	Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors.
8/2006	Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents.
1/2006	The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on alpha7 nicotinic receptors in hippocampal neurons: clinical implications for treatment of Alzheimer's disease.
6/2003	Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edson X Albuquerque Research Topics

Disease

13	Alzheimer Disease (Alzheimer's Disease) 10/2020 - 05/2002
8	Schizophrenia (Dementia Praecox) 10/2012 - 12/2002
6	Poisoning 12/2020 - 08/2006
3	Cognitive Dysfunction 01/2017 - 03/2005
1	Intellectual Disability (Idiocy) 09/2020
1	Neurodevelopmental Disorders 09/2020
1	Autism Spectrum Disorder 09/2020
1	Tremor (Tremors) 01/2017
1	Neurologic Manifestations (Neurological Manifestations) 08/2014
1	Memory Disorders (Memory Loss) 05/2013
1	Seizures (Absence Seizure) 09/2010
1	Organophosphate Poisoning 01/2010
1	Atrophy 01/2010
1	Mental Disorders (Mental Disorder) 07/2007
1	Wounds and Injuries (Trauma) 07/2006
1	Tobacco Use Disorder (Nicotine Dependence) 05/2005
1	Body Weight (Weight, Body) 03/2004
1	Parkinson Disease (Parkinson's Disease) 12/2002
1	Nervous System Diseases (Neurological Disorders) 12/2002

Drug/Important Bio-Agent (IBA)

11	Galantamine (Galanthamine)FDA LinkGeneric 10/2020 - 05/2002
9	Pharmaceutical PreparationsIBA 10/2020 - 03/2005
7	SomanIBA 10/2020 - 08/2006
6	Nerve AgentsIBA 10/2020 - 08/2006
6	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 05/2012 - 12/2002
5	Kynurenic Acid (Kynurenate)IBA 10/2012 - 04/2005
5	LigandsIBA 12/2009 - 05/2002
3	InsecticidesIBA 12/2020 - 08/2006
3	KynurenineIBA 05/2012 - 07/2007
2	AcetylcholinesteraseIBA 10/2020 - 07/2006
2	Chlorpyrifos (Lorsban)IBA 01/2017 - 05/2013
2	Cholinergic Agents (Cholinergics)IBA 08/2014 - 01/2010
2	SarinIBA 01/2010 - 08/2006
2	AntidotesIBA 01/2010 - 12/2009
2	Nicotine FDA Link 01/2009 - 05/2005
2	Paraoxon (E600)IBA 08/2006 - 03/2004
2	N-Methylaspartate (NMDA)IBA 04/2005 - 03/2005
1	Organophosphorus CompoundsIBA 10/2020
1	Malathion (Karbofos)FDA LinkGeneric 09/2020
1	Atropine FDA LinkGeneric 01/2010
1	Cholinesterases (Cholinesterase)IBA 12/2009
1	Apomorphine FDA Link 02/2007
1	Parathion (Ethyl Parathion)IBA 08/2006
1	Acetylcholine (Acetylcholine Chloride)FDA Link 07/2006
1	Choline (Choline Chloride)IBA 07/2006
1	Neurotransmitter Agents (Neurotransmitter)IBA 07/2006
1	Bupropion (Wellbutrin)FDA LinkGeneric 05/2005
1	Biological ProductsIBA 05/2005
1	alpha7 Nicotinic Acetylcholine ReceptorIBA 04/2005
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 03/2005
1	Memantine (Namenda)FDA Link 03/2005
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 05/2002

Therapy/Procedure

3	Therapeutics 08/2014 - 08/2006